N/A N=71 Evaluation of HQ® Matrix Medical Wound Dressing for Healing of Donor Site Wounds
Donor Site Wound
Primary: Time to Wound Healing — 9.86; 11.35 Days — p=0.02
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=150 Randomized Trial of Iron Supplementation to Prevent Anemia in Very-low-birth-weight Infants
Anemia
Primary: Hematocrit (Hct) — 29.2; 28.3 percentage of red blood cells in blood
N/A N=44 Sacro-Spinous Ligaments Anterior Apical Anchoring
Pelvic Organ Prolapse
Primary: The Change With Distance Between the Vaginal Apex and the Introitus — -4.4 centimeters
N/A N=47 Cognitive Behavioral Therapy for Diabetic Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Numeric Rating Scale (NRS) Pain Intensity — -0.83; -0.45 units on a scale — p=0.47
Phase 3 N=100 Evaluation of the CR Neuromodulation Treatment for Tinnitus
Tinnitus
Primary: Tinnitus Handicap Questionnaire (THQ) — 3.75; 4.02 units on a scale
Phase 2 N=8 Incretin Effect and Use After Clinical Islet Transplantation
Type 1 Diabetes
Primary: The Primary Endpoint Will be Insulin Independence After 6 Months of Therapy. — 0.25 proportion of participants — p=< 0.05
N/A N=5 HIV Posterior Cheek Enlargement
HIV Posterior Cheek Enlargement
Primary: Percentage Change in Volume of the Masseter Muscle From Baseline to 12 Weeks After Treatment With Botulinum Toxin A — 21.4 percentage reduction in masseter volume
Phase 3 N=506 A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
Schizophrenia
Primary: Time to Relapse During the Double-Blind Phase — 395.0; NA Days
Phase 3 N=30 Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B
Hemophilia B
Primary: Occurence of Factor IX (FIX) Inhibitor Development — 0; 0; 0; 0 percentage of participants
Phase 2 N=110 Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation
Intracerebral Hemorrhage
Primary: Safety Outcome Number 1: Rate of Mortality — 9.5; 14.8; 7.1 percentage of participants — p=0.324
Phase 4 N=30 Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis
Chronic Stable Plaque Psoriasis
Primary: The Primary Endpoint Will be the Percentage of Patients Achieving a 75% Reduction in the Psoriasis Area and Severity Index at Week 12. — 83 percent
Phase 3 N=239 A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q
Anemia
Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC) — 2.5; 26.9…
Phase 2 N=24 Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
Age-related Macular Degeneration
Primary: Highest Tolerated Dose (HTD) of AGN-150998 — 4.2 mg
Phase 4 N=48 Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment
Ketosis Prone Diabetes · Diabetes Ketoacidosis · Hyperglycemia
Primary: Length of Remission — 472; 589; 111 days
N/A N=108 Effect of Root Canal Treatment (Versus no Treatment) for Patients With Tooth Infections and Toothaches
Postoperative Pain
Primary: Percent of Patients With Success as Defined by no or Mild Pain as Analyzed on a VAS Scale and no Narcotic Use — 52; 43 percentage of participants